Shots:
Innovent has reported the P-III (RESTORE-3) trial data assessing Sycume(teprotumumab N01/IBI311) vs PBO in Chinese pts (n=116) with inactive thyroid eye disease (bilateral CAS ≤ 2 points)
Trial met its 1EP at Wk. 24, showing higher proptosis response rate as compared to PBO (60.4% vs. 23.5%), plus in 2EP, Sycume showed LS Mean change…
